Contineum Therapeutics (CTNM) Change in Acquisitions & Divestments (2023 - 2026)

Contineum Therapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $50.6 million for Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments rose 28.65% year-over-year to $50.6 million; the TTM figure through Jun 2026 stood at $179.8 million (up 2.47% YoY), while the FY2025 annual figure was $159.0 million, up 1.18% from the prior year.
• Change in Acquisitions & Divestments for Q2 2026 stood at $50.6 million, down from $58.1 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $58.1 million in Q1 2026, with the low at $12.6 million in Q3 2023.
• The 4-year median for Change in Acquisitions & Divestments is $38.3 million (2025), against an average of $35.8 million.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments jumped 235.53% in 2024, then slipped 20.35% in 2025.
• Contineum Therapeutics' Change in Acquisitions & Divestments stood at $31.3 million in 2023, then soared by 44.03% to $45.1 million in 2024, then declined by 17.3% to $37.3 million in 2025, then surged by 35.7% to $50.6 million in 2026.
• Business Quant data shows CTNM's Change in Acquisitions & Divestments at $50.6 million in Q2 2026, $58.1 million in Q1 2026, and $37.3 million in Q4 2025.